arrow
M

Murat Özbalak

Istanbul University
H指数:10
被引数:312

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

IDH1 Mutations in Acute Myeloid Leukemia: Frequency and Clinical Features in the Context of FLT3 and NPM1 Co-Mutations—A Single-Center Study from Turkey

急性髓系白血病中IDH1突变:在FLT3和NPM1共突变背景下的频率及临床特征——来自土耳其的单中心研究

2026-07-260
OA
Exploring an independent association between rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone dose intensity and clinical outcomes in large B-cell lymphoma: Analyses of subsequent endpoints following a complete response in a real-world cohort of 1369 patients

探索利妥昔单抗-环磷酰胺-多柔比星-长春新碱-泼尼松剂量强度与弥漫性大B细胞淋巴瘤临床结局的独立相关性:对真实世界1369例患者完全缓解后后续终点的分析

Cancer
IF5.1
2026-01-010
PRE
Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group

根据既往Brentuximab Vedotin(BV)暴露情况,接受ASCT后应用BV作为维持治疗的霍奇金淋巴瘤患者的结局。EBMT淋巴瘤工作组与Geltamo、FIL、Lysarc和土耳其淋巴瘤组的回顾性分析。

BLOOD
IF23.1
2024-11-050
PRE
Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data

Glofitamab治疗复发/难治性弥漫性大b细胞淋巴瘤: 真实世界数据

2023-05-2213
OA
Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study
2021-06-2512
PREAI
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
2020-06-0716
PREAI
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
2017-10-0149
OAAI